Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 149.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 279,807 shares of the biopharmaceutical company’s stock after acquiring an additional 167,423 shares during the quarter. Allianz Asset Management GmbH owned about 0.52% of Emergent Biosolutions worth $2,468,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in EBS. Millennium Management LLC lifted its position in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after acquiring an additional 1,020,582 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Emergent Biosolutions by 108.9% during the second quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock worth $8,162,000 after purchasing an additional 666,708 shares during the period. Bank of America Corp DE lifted its holdings in shares of Emergent Biosolutions by 232.1% during the second quarter. Bank of America Corp DE now owns 309,947 shares of the biopharmaceutical company’s stock worth $1,977,000 after purchasing an additional 216,630 shares during the period. Prescott Group Capital Management L.L.C. boosted its position in Emergent Biosolutions by 23.1% in the second quarter. Prescott Group Capital Management L.L.C. now owns 772,771 shares of the biopharmaceutical company’s stock valued at $4,930,000 after buying an additional 145,100 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Emergent Biosolutions by 17.0% in the 2nd quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock worth $6,216,000 after buying an additional 141,274 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Emergent Biosolutions news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total transaction of $263,148.48. Following the transaction, the director directly owned 98,417 shares of the company’s stock, valued at $1,178,051.49. The trade was a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EBS has been the topic of a number of recent research reports. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. Weiss Ratings restated a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a report on Tuesday, December 16th. Finally, Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 30th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Stock Performance

NYSE EBS opened at $11.00 on Thursday. The company has a fifty day moving average of $11.99 and a two-hundred day moving average of $10.09. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $14.06. The company has a market capitalization of $577.51 million, a PE ratio of 8.46 and a beta of 2.35. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.